Masters Pharmaceutical is a pharmaceutical wholesaler that provides pharmacies with pharmaceutical products, including brands, generics, and OTC medications.

Masters Pharmaceutical

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

James Wood Johnson

Edward Mead Johnson

Robert Wood Johnson

Johnson & Johnson

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly

Eli Lilly and Company

Merck for Mothers is focused on improving maternal health outcomes by promoting safe, high-quality, respectful maternal health care worldwide, self-described as reaching more than 30 million women.

Metric
Company Name	Masters Pharmaceutical	Johnson & Johnson	Eli Lilly and Company	Merck for Mothers
Symbol		JNJ	LLY
MSH ID	COM:MASTERSRX	COM:JNJ	COM:LILLY	COM:MERCKFORMOTHERS
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare & Health Services
Industry	Pharmaceutical Distribution	Drug Manufacturers - General	Drug Manufacturers - General	Health & Social Services
Country	US	US	US	US
Stage
Employee Count		131.90K	43K
Website	mastersrx.com	jnj.com	lilly.com	merckformothers.com
LinkedIn		johnson-&-johnson
Founders

Metric
Market Cap		359.63B	893.17B
Enterprise Value
Monthly Web Traffic	98.43K	2.26M
Web Traffic Growth	-0.03	0.02
Valuation
Raised Capital

Metric
Revenue	85.15B	34.12B
Revenue (LTM)
Revenue (NTM)
Gross Profit	58.41B	27.55B
EBITDA	29.34B	12.46B
Operating Income	21.85B	10.33B
Net Income	14.17B	5.24B
EPS	5.59	5.82
Diluted EPS	5.53	5.80
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.71	0.81
Operating Profit Margin	0.30	0.27
EBITDA Margin	0.34	0.37
Net Profit Margin	0.45	0.23
Return on Equity	0.57	0.61
Return on Assets	0.24	0.10
Return on Capital Employed	0.21	0.23

COM:MASTERSRX

Masters Pharmaceutical

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	10.85	127.25
P/B Ratio	5.27	56.57
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.66	27.04
EV Multiple	13.83	115.09

Metric
Days Sales Outstanding	56.66	117.94
Days Payables Outstanding	98.44	129.90
Days Inventory Outstanding	178.66	327.50
Operating Cycle	245.26	452.72
Cash Conversion Cycle	115.35	323.73
Asset Turnover	0.56	0.56

Metric
Operating Cash Flow	22.79B	4.24B
Free Cash Flow	18.25B	-3.15B
Cash Flow to Debt	0.78	0.17
Operating Cash Flow/Sales	0.28	0.14
Free Cash Flow Yield	0.04	-0.00

Metric
Cash & Equivalents	21.86B	2.82B
Accounts Receivable	-624M	-2.45B
Inventory	11.18B	5.77B
Goodwill	36.56B	4.94B
Debt to Capitalization	0.37	0.70
Debt to Assets	0.18	0.35
Current Ratio	1.21	1.05
Quick Ratio	0.94	1.03

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.02
R&D to Revenue	0.16	0.27
SG&A to Revenue	0.06	0.22